Evaluate Alternative Revolutionary Reimbursement Models To Craft A Sustainable Business Model For Cell And Gene Therapies

During Reuter’s Cell and Gene Therapy USA 2022 conference, Senior Vice President, Market Economics, David Senior, was joined by fellow industry experts, Heather McDonald, Vice President, Market Access for CGT + Digital at Bayer, Burcu Kazazoglu Taylor, Senior Director, Global Value and Access, at Novartis Gene Therapies, and Michael Sherman, Executive Vice President and Chief Medical Officer at Point 32, to discuss new innovative payment strategies for cell and gene therapies.

Access the recording to learn more about the key features of successful innovative pricing and reimbursement models, and outcomes-based agreements in particular, and about the ways to advance those strategies for cell and gene therapies.